According to McCulloch, Xeris is the only glucagon company “out there advocating for the new guidelines and promoting in the space.” Amphastar's intranasal glucagon dry powder, Baqsimi ...

State of Alaska Department of Revenue lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.6% in the fourth quarter, HoldingsChannel reports. The fund owned 21,325 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

The wife provided deputies with a Glucagon Nasal Powder spray (BAQSIMI) to raise his blood sugar level and gave permission for deputies to use a baton to break the passenger side window to access ...

Intranasal (IN) delivery of medications is ... topical anesthetics, glucagon for hypoglycemia, and agents for epistaxis control. Many new medications, or new uses for common medications via ...

Glucagon is a recognised therapy for the disorder ... 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

Baqsimi contains glucagon, a hormone that your body makes ... This raises your blood sugar level. Baqsimi is a nasal spray. It’s given as one spray into one nostril during an episode of severe ...

Since intranasal S-ketamine was approved by the U.S. FDA and the ... and emotions (Guerrero-Hreins et al., 2021; Pinna, 2023). Glucagon-like peptide 1 (GLP-1), released from the colon, reaches the ...